TY - JOUR
T1 - In vitro antioxidative activity of ( - )-epicatechin glucuronide metabolites present in human and rat plasma
AU - Natsume, Midori
AU - Osakabe, Naomi
AU - Yasuda, Akiko
AU - Baba, Seigo
AU - Tokunaga, Takashi
AU - Kondo, Kazuo
AU - Osawa, Toshihiko
AU - Terao, Junji
PY - 2004/12
Y1 - 2004/12
N2 - Recently we identified four conjugated glucuronide metabolites of epicatechin, (-)-epicatechin-3′-O-glucuronide (E3′G), 4′-O-methyl-(-)-epicatechin-3′-O-glucuronide (4′ ME3′G), (-)-epicatechin-7-O-glucuronide (E7G) and 3′-O-methyl-(-)-epicatechin-7-O-glucuronide (3′ME7G) from plasma and urine. E3′G and 4′ME3′G were isolated from human urine, while E7G and 3′ME7G were isolated from rats that had received oral administration of (-)-epicatechin (Natsume et al. (2003), Free Radic. Biol. Med. 34, 840-849). It has been suggested that these metabolites possess considerable in vivo activity, and therefore we carried out a study to compare the antioxidant activities of the metabolites with that of the parent compound. This was achieved by measuring superoxide scavenging activity, reduction of plasma TBARS production and reduced susceptibility of low-density-lipoprotein (LDL) to oxidation. (-)-Epicatechin was found to have more potent antioxidant activity than the conjugated glucuronide metabolites. Both (- -epicatechin and E7G had marked antioxidative properties with respect to superoxide radical scavenging activity, plasma oxidation induced by 2,2′-azobis-(2-aminopropane) dihydrochloride (AAPH) and LDL oxidation induced by copper ions or 2,2′-azobis(4-methoxy-2,4-dimethylvaleronitrile) (MeO-AMVN). In contrast, the other metabolites had light antioxidative activities over the range of physiological concentrations found in plasma.
AB - Recently we identified four conjugated glucuronide metabolites of epicatechin, (-)-epicatechin-3′-O-glucuronide (E3′G), 4′-O-methyl-(-)-epicatechin-3′-O-glucuronide (4′ ME3′G), (-)-epicatechin-7-O-glucuronide (E7G) and 3′-O-methyl-(-)-epicatechin-7-O-glucuronide (3′ME7G) from plasma and urine. E3′G and 4′ME3′G were isolated from human urine, while E7G and 3′ME7G were isolated from rats that had received oral administration of (-)-epicatechin (Natsume et al. (2003), Free Radic. Biol. Med. 34, 840-849). It has been suggested that these metabolites possess considerable in vivo activity, and therefore we carried out a study to compare the antioxidant activities of the metabolites with that of the parent compound. This was achieved by measuring superoxide scavenging activity, reduction of plasma TBARS production and reduced susceptibility of low-density-lipoprotein (LDL) to oxidation. (-)-Epicatechin was found to have more potent antioxidant activity than the conjugated glucuronide metabolites. Both (- -epicatechin and E7G had marked antioxidative properties with respect to superoxide radical scavenging activity, plasma oxidation induced by 2,2′-azobis-(2-aminopropane) dihydrochloride (AAPH) and LDL oxidation induced by copper ions or 2,2′-azobis(4-methoxy-2,4-dimethylvaleronitrile) (MeO-AMVN). In contrast, the other metabolites had light antioxidative activities over the range of physiological concentrations found in plasma.
KW - ( - )-epicatechin metabolites
KW - Antioxidative activity
KW - Low-density-lipoprotein(LDL)
KW - Plasma oxidation
KW - Superoxide radical
UR - http://www.scopus.com/inward/record.url?scp=11044228866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11044228866&partnerID=8YFLogxK
U2 - 10.1080/10715760400022087
DO - 10.1080/10715760400022087
M3 - Article
C2 - 15763958
AN - SCOPUS:11044228866
SN - 1071-5762
VL - 38
SP - 1341
EP - 1348
JO - Free Radical Research
JF - Free Radical Research
IS - 12
ER -